NOTE J — STOCK-BASED COMPENSATION

Stock-based compensation represents the cost related to stock-based awards granted to our associates and directors; these awards include restricted stock, restricted stock units, performance stock, performance stock units and SARs. We grant stock-based incentive awards to our associates and our directors under various share-based compensation plans. Plans that are active or provide for stock option grants or share-based payment awards include the Amended and Restated 2014 Omnibus Equity and Incentive Plan (the “2014 Omnibus Plan”) and the 2024 Omnibus Equity and Incentive Plan (the “2024 Omnibus Plan”), which include provisions for grants of restricted stock, restricted stock units, performance shares, performance units, unrestricted stock and SARs. The shares available for grant out of the 2014 Omnibus Plan have expired, therefore, all future grants will be issued from the 2024 Omnibus Plan until its expiration or replacement.

We measure stock-based compensation cost at the date of grant, based on the estimated fair value of the award. We recognize the cost as expense on a straight-line basis (net of estimated forfeitures) over the related vesting period.

SARs

SARs are awards that allow our associates to receive shares of our common stock at a fixed price. We grant SARs at an exercise price equal to the stock price on the date of the grant. The fair value of SARs granted is estimated as of the date of grant using a Black-Scholes option-pricing model. The Black-Scholes option-pricing model was developed for use in estimating the fair value of traded options that have no vesting restrictions and are fully transferable. The risk-free rate for periods within the contractual life of the option is based on the U.S. Treasury yield curve in effect at the time of grant. The expected life of options granted is derived from the input of the option-pricing model and represents the period of time that options granted are expected to be outstanding. Expected volatility rates are based on historical volatility of shares of our common stock.

The 2024 Omnibus Plan was approved by our stockholders on October 3, 2024. The 2024 Omnibus Plan provides us with the flexibility to grant a wide variety of stock and stock-based awards, as well as dollar-denominated performance-based awards, and is the primary stock-based award program for covered associates. The plan replaces the 2014 Omnibus Plan, which expired under its own terms in October 2024. SARs are issued at fair value at the date of grant, have up to ten-year terms and have graded-vesting terms over four years. Compensation cost for these awards is recognized on a straight-line basis over the related vesting period. Currently all SARs outstanding are to be settled with stock.

At May 31, 2026, the aggregate intrinsic value and weighted-average remaining contractual life of options outstanding was $44.0 million and 5.45 years, respectively, while the aggregate intrinsic value and weighted-average remaining contractual life of options exercisable was $40.6 million and 4.45 years, respectively.

At May 31, 2026, the total unamortized stock-based compensation expense related to SARs that were previously granted was $10.2 million, which is expected to be recognized over a weighted-average of 2.50 years. We anticipate that approximately 2.1 million shares at a weighted-average exercise price of $86.11 and a weighted-average remaining contractual term of 5.44 years are vested or expected to vest under these plans.

Restricted Stock Plans

We also grant stock-based awards, which may be made in the form of restricted stock, restricted stock units, performance shares and performance stock units. These awards are granted to eligible associates or directors and entitle the holder to shares of our common stock as the award vests. The fair value of the awards is determined and fixed based on the stock price at the date of grant. A description of our restricted stock plans follows.

Under the 2014 Omnibus Plan, a total of 6,000,000 shares of our common stock may be subject to awards. Of those issuable shares, up to 3,000,000 shares of common stock may be subject to “full-value” awards. In October 2019, shareholders approved an amendment to the 2014 Omnibus Plan making an additional 5,000,000 shares of common stock subject to awards. Of those additional issuable shares, 2,250,000 shares may be subject to “full-value” awards similar to those issued under the 2014 Omnibus Plan.

Under the 2024 Omnibus Plan, a total of 5,000,000 shares of our common stock may be subject to awards. Of those issuable shares, up to 2,500,000 shares of common stock may be subject to “full-value” awards. Nonvested restricted shares/units of common stock under both the 2014 Omnibus Plan and 2024 Omnibus Plan are eligible for dividend payments, while performance stock units are not eligible for dividend payments unless and until such units vest. Dividends are then paid based on the units that have vested.

The weighted-average grant-date fair value was $110.54, $114.14 and $93.74 for the fiscal years ended May 31, 2026, 2025 and 2024, respectively. The restricted stock and performance stock cliff vest after three years. At May 31, 2026, remaining unamortized deferred compensation expense for performance-earned restricted stock totaled $14.3 million. The remaining amount is being amortized over the applicable vesting period for each participant.

PSUs have been granted to certain executives and the awards are contingent upon the level of attainment of performance goals for the three-year performance period. Vesting of 50% of the PSUs relates to compounded annualized growth rates in adjusted revenue for the period, and the vesting of the remaining 50% relates to an increase in EBIT margin, measured at the end of the three-year performance period. The number of PSUs that may vest with respect to the achievement of the performance goals may range from 0% to 200% of the PSUs granted under this program. Compensation cost for these awards has been recognized on a straight-line basis over the related performance period, with consideration given to the probability of attaining the performance goals.

During fiscal 2026, shares were awarded under the 2024 Omnibus Plan to our non-employee directors, for the purpose of recruiting and retaining directors and to align the interests of directors with the interests of our stockholders. These awards cliff vest after three years. The shares available for grant out of the 2014 Omnibus Plan have expired, therefore, all future grants will be issued from the 2024 Omnibus Plan.

The weighted-average grant-date fair value was $117.19, $127.65 and $98.61 for the fiscal years ended May 31, 2026, 2025 and 2024, respectively. Unamortized deferred compensation expense relating to restricted stock grants for directors of $2.3 million at May 31, 2026, is being amortized over the applicable remaining vesting period for each director.

During fiscal 2026, a total of 18,261 shares were awarded under the 2024 Omnibus Plan to certain associates as supplemental retirement benefits, generally subject to forfeiture. The shares vest upon the latter of attainment of age 55 and the fifth anniversary of the May 31st immediately preceding the date of the grant. In April 2026, the grant provisions were amended to remove the post vesting restriction which previously lapsed upon associates’ retirement. The modification has no impact on compensation cost recognized. The following table sets forth such awards for the year ended May 31, 2026:

The weighted-average grant-date fair value was $110.59, $114.26 and $93.51 for the fiscal years ended May 31, 2026, 2025 and 2024, respectively. As noted above, no shares remain available for future grant under the 2007 Plan and the 2014 Omnibus Plan has expired, and future issuances of shares as supplemental retirement benefits are made under the 2024 Omnibus Plan. At May 31, 2026, unamortized stock-based compensation expense of $4.1 million is being amortized over the applicable vesting period associated with each participant.

The fair value of the nonvested restricted share awards have been calculated using the market value of the shares on the date of issuance. Total unrecognized compensation cost related to all nonvested awards of restricted shares of common stock was $44.1 million as of May 31, 2026. The remaining weighted-average contractual term of nonvested restricted shares at May 31, 2026 is the same as the period over which the remaining cost of the awards will be recognized, which is approximately 2.15 years. We did not receive any cash from associates as a result of associate vesting and release of restricted shares for the year ended May 31, 2026.